ArticleAnimal models and experimental medicine2025
Innovative insights into the effects of a high-sucrose diet on pancreatic health and the therapeutic role of empagliflozin in type 2 diabetes: An experimental study.
Article in Animal models and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Innovative insights into the effects of a high-sucrose diet on pancreatic health and the therapeutic role of empagliflozin in type 2 diabetes: An experimental study.Animal models and experimental medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 Diabetes (T2D) is a growing global health issue, often aggravated by excessive sugar intake. Chronic high-sucrose diets contribute to insulin resistance, oxidative stress, and pancreatic dysfunction, worsening metabolic health. Sodium-glucose co-transporter 2 (SGLT2) inhibitors, like empagliflozin, show potential in improving glycemic control and metabolic parameters, but their effects on pancreatic efficiency in sugar-induced T2D are not well understood. This study aimed to explore the effects of empagliflozin on metabolic and pancreatic protection in a high-sucrose diet-induced T2D model. Male Wistar rats were divided into four groups: normal, normal-treated, diabetic, and diabetic-treated (n = 8 per group). Diabetes was induced with a 35% sucrose solution for 8 weeks, followed by a low-dose streptozotocin (STZ) injection. Treated groups received empagliflozin (15 mg/kg/day) for the duration. Biochemical markers, including fasting blood sugar (FBS), lipid profile, insulin levels, and oxidative stress markers, were measured. Insulin resistance (HOMA-IR) and pancreatic function (HOMA-B) were assessed. Histological analysis of pancreatic tissues was performed. The high-sucrose diet increased FBS, insulin resistance, and oxidative stress, while decreasing pancreatic function and islet diameter. Empagliflozin treatment lowered FBS (p = 0.001), improved insulin sensitivity (p = 0.001), reduced triglycerides (p = 0.001), and LDL (p = 0.05). It also enhanced antioxidant enzymes, reduced lipid peroxidation (MDA, p = 0.001), and preserved pancreatic islet structure (p = 0.001). A high-sucrose diet negatively affects metabolic health and pancreatic function. Empagliflozin mitigates these effects by improving metabolism, reducing oxidative stress, and preserving pancreatic integrity, suggesting its potential as a therapeutic agent in diabetes related to excessive sugar consumption.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.